How long will yervoy's patent last?

Short answer: there isn’t a single expiration date for Yervoy (ipilimumab). It depends on exactly which patents or exclusivity you’re talking about, and in which country or region.

What to know

- US patent terms
- Patent term is typically 20 years from the earliest non-provisional filing date, with possible adjustments/extension for regulatory delays.
- Ipilimumab is covered by multiple patent families held by Bristol Myers Squibb and collaborators; core patents may expire at different times depending on filing date and any term adjustments.
- Regulatory data exclusivity (US)
- For a new biologic, the BPCIA provides 12 years of data exclusivity from FDA approval.
- Ipilimumab was approved in 2011, so the 12-year data exclusivity would run until around 2023, during which time a biosimilar would generally not be allowed to rely on the original clinical data.
- EU and other regions
- The EU has its own framework (data exclusivity plus market exclusivity, with potential extensions for new indications). Expiry patterns differ from the US.
- Practical takeaway
- Even if patent protection lapses for core ipilimumab patents, there can still be patent protection on manufacturing processes, formulations, or specific indications, and data exclusivity can delay competition.
- As of recent years, many core patents have reached or are nearing expiration in various regions, but exact dates vary by patent family and country.

If you want precise dates, tell me:
- Which country or region you’re interested in (US, EU, another country)?
- Do you want patent expiration dates, regulatory exclusivity dates, or both?

I can guide you to the current patent status and summarize which rights remain active.